Plain-English translation of NCT07089121 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing , a new cell-based therapy designed to help children, teenagers, and young adults whose bodies are attacking themselves due to autoimmune diseases. The trial will first determine the safest and most effective dose of the medication, then give that dose to a larger group to see if it actually works and is well tolerated. Researchers want to understand whether this treatment can reduce symptoms and improve quality of life for young people with lupus, vasculitis, myasthenia gravis, or dermatomyositis.
These four autoimmune diseases can be very serious and hard to control in children and young adults, even with current treatments. This medication uses special immune cells in a completely new way, and early research suggests it might help calm down the overactive immune system in ways that older medications cannot.
You likely qualify if…
You likely don't qualify if…
The trial has two parts. In Part 1, you will receive six infusions of the medication over several weeks, with the dose slowly increased to find the safest level. In Part 2, participants receive the best dose from Part 1 as infusions once a week for 6 weeks. You will have regular blood tests and visits to monitor how you respond and watch for any side effects. The whole study lasts several months, and you'll work closely with the research team to track how you feel.
AI-generated summary from trial data · Aug 10, 2026 · Not medical advice
United States